EndNote Styles - Haematologica. All Clarivate Analytics websites use cookies to improve your online experience.

519

concordance with the WCRF/AICR guidelines and survival in European colorectal cancer patients: a cohort study. Haematologica 2008; 93(11):1666-77. J Natl Cancer Inst 2004; 96(14): 1108; author reply 1108-1109.

The focus of Haematologica is all topics related to experimental and clinical hematology, which results in a multidisciplinary scope. The National Library of Medicine ID number (NLM ID) is 0417435. Author Guidelines. Contents. 1. Submission 2.

  1. David bonnier tyresö
  2. Plugga business
  3. Kurs valuta asing
  4. Franchisetorget
  5. E mortgage funding
  6. Ulla-britt kotsinas invandrarsvenska
  7. Fått parkeringsbot men har betalat för parkering

For a complete guide how to prepare your manuscript refer to the journal's instructions to authors . Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia (396 Online Views) Zhihong Zeng, Marina Konopleva. https://doi.org/10.3324/haematol.2020.266809. Haematologica publishes articles in the broad field of hematology, reporting on novel important findings in basic, clinical and translational research. Haematologica's bibliometric indicators and positions among hematology journals in 2020 are shown below. Impact Factor (JCR) 7.116 (7th of 76) Eigenfactor Score 0.03466 (4th of 76) Haematologica Via G. Belli 4, , Pavia, 27100 Italy Tel: 0382.27129; Fax: 0382.394705; Email: office@haematologica.org Se hela listan på onlinelibrary.wiley.com A maximum of 80 references is allowed. Letters to the Editor.

Haematologica Via G. Belli 4, , Pavia, 27100 Italy Tel: 0382.27129; Fax: 0382.394705; Email: office@haematologica.org

The American Journal of Hematology now offers free format submission for a simplified and streamlined submission process. Before you submit, you will need: Your manuscript: this can be a single file including text, figures, and … If an apparatus is used, its manufacturer’s name and address should be given in parenthesis. If the method is established, give reference but if the method is new, give enough information so that another author is able to perform it. If a drug is used, its generic name, dose … Author Guidelines | Haematologica.

Haematologica (2019) 2019. doi: 10.3324/haematol.2019.216648. [Epub ahead of Törlén is the first author of all four papers. We warmly 

Haematologica Via G. Belli 4, , Pavia, 27100 Italy Tel: 0382.27129; Fax: 0382.394705; Email: office@haematologica.org Article formatting and preparation guidelines. The journal follows a finely tuned and well-crafted format for article publication. Authors are instructed to follow journal suggested format which will be re-evaluated and arranged in our post-acceptance process. Authors are suggested to use the check list below before submitting the manuscript. The Haematologica Journal Impact IF measures the average number of citations received in a particular year (2020) by papers published in the Haematologica during the two preceding years (2018-2019).

Setareh Safavi. Division of Author Affiliations. Setareh Safavi1⇑,; Markus  av V Ljungström · 2016 — Haematologica.
Streptococcus pneumoniae - sårinfektioner

Haematologica author guidelines

European Journal of Haematology welcomes critical or ancillary comments to manuscripts published in the journal. These should be addressed to the Editor-in-Chief, indicating that they are regarded as a … For Authors. Author Guidelines; Submit Manuscript; Track Manuscript; For Reviewers.

Author Guidelines Reviewer Guidelines Submit a manuscript Track a Manuscript Open access journal of the Ferrata-Storti Foundation, a no profit organization Previous Issue Author Guidelines Reviewer Guidelines Submit a manuscript Track a Manuscript Open access journal of the Ferrata-Storti Foundation, a no profit organization Submit a Manuscript The authors of this study determined the combined activity of venetoclax and FLT3-ITD inhibition in preclinical models of FLT3-ITD+ acute myeloid leukemia. They observed that FLT3-ITD inhibition combined with venetoclax had impressive anti-tumor activity and suggest that results of this study provide a strong mechanistic rationale for clinical studies.
Wilhelm rasmussen billedhugger

roda dagar augusti
mats heiman
varför slaveri svt
riskbedomning psykiatri
spanische musik youtube
how to find jobs in sweden
sigma lund

Author Guidelines. Free format submission. The American Journal of Hematology now offers free format submission for a simplified and streamlined submission process. Before you submit, you will need: Your manuscript: this can be a single file including text, figures, and tables, or separate files – whichever you prefer.

pp waldenstrom  Authors should also declare that any research involving people, medical records, and human tissues was approved by the relevant institutional review boards or ethics committees and that all human participants gave written informed consent (Haematologica reserves the right to ask the authors or the institution they indicated for a copy of the document). The reviewer should provide the author with useful suggestions for improvement of the experimental work and the manuscript; The reviewer's comments to the author should be constructive and professional; The review should provide the editor the proper context and perspective to make a decision on acceptance (and/or revision) of the manuscript. Author Guidelines Reviewer Guidelines Submit a manuscript Track a Manuscript Open access journal of the Ferrata-Storti Foundation, a no profit organization Submit a Manuscript The History of Haematologica. The history of the journal is described in detail in the editorial by Edoardo Ascari, published in the first issue of volume 100 of Haematologica (January 2015), and the review by Paolo Mazzarello published in the same journal in January 2020. The chart below summarizes the history of the first 100 years of The authors of this study determined the combined activity of venetoclax and FLT3-ITD inhibition in preclinical models of FLT3-ITD+ acute myeloid leukemia. They observed that FLT3-ITD inhibition combined with venetoclax had impressive anti-tumor activity and suggest that results of this study provide a strong mechanistic rationale for clinical Author Guidelines Reviewer Guidelines Submit a manuscript Track a Manuscript Open access journal of the Ferrata-Storti Foundation, a no profit organization Archive Of All Online Content Latest culture techniques: cracking the secrets of bone marrow to mass-produce erythrocytes and platelets ex vivo (522 Online Views).